NCT Number,Study Title,Study URL,Acronym,Study Status,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Age,Phases,Study Type,Study Design,Other IDs,Study Documents
NCT00732771,Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism,https://beta.clinicaltrials.gov/study/NCT00732771,,COMPLETED,NO,Primary Hyperaldosteronism,DRUG: LCI699,"Systolic blood pressure over a 7-week forced titration treatment period, 7 weeks","Plasma and urine hormone levels and electrolytes, diastolic blood pressure and drug pharmacokinetics over a 7-week forced titration treatment period, 7 weeks",,Novartis,,"ADULT, OLDER_ADULT",PHASE2,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,CLCI699A2206,
